Tilray’s fiscal year 2025 earnings, released on July 28, reflect steady progress despite strategic challenges. The company achieved net revenue of $821 million, increasing 4% from $789 million the prior year. That figure rises to $834 million when adjusted for constant currency. This revenue growth was partly tempered by a $35 million impact from international permit delays and strategic priorities in Canada, including a $15 million revenue hit from deemphasizing vape products. This helped Tilray preserve h ...

The stock remains significantly down from its all-time highs.Is this the year Tilray Brands (TLRY -2.42%) finally starts its comeback? During the past five years, the company has lagged broader equities as the cannabis industry, where it is a leader, continues to fall far short of expectations. However, Tilray Brands has been on fire this year, and during the past six months alone, the stock is up more than 150% (as of Oct. 2). Yet, the shares are still well into penny stock territory and are currently trad ...

If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market to start October, consider joining Out Fox The Street .Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relation ...

Where Is Cannabis Legal? A Guide To All 50 States https://t.co/vI1UPSraOf https://t.co/n4mv6tKZQA ...

Industry Overview - The U.S. cannabis industry generated over $33 billion in sales during 2024, making it one of the fastest-growing consumer sectors, with projections of annual sales surpassing $56 billion by 2030 [1] - Federal rescheduling efforts could ease tax burdens for cannabis companies, while more states are preparing adult-use legalization measures, increasing growth opportunities for multi-state operators [1][5] - The sector is characterized by volatility, necessitating careful evaluation of fundamentals and sector catalysts [1][12] Company Highlights Green Thumb Industries (OTC: GTBIF) - Green Thumb Industries operates over 100 dispensaries across 14 states, focusing on high-demand, limited-license markets, and has confirmed 108 locations with steady growth [3][5] - The company reported quarterly revenue of approximately $293 million in 2025, reflecting a year-over-year increase, with adjusted EBITDA around $83 million and operating cash flow of $56 million [4][5] - Green Thumb has a balance sheet with $177 million in cash, allowing for financial flexibility and continued investment [5] Glass House Brands (OTC: GLASF) - Glass House Brands focuses on California, managing 10 dispensaries and emphasizing large-scale greenhouse cultivation and efficient production [6][8] - The company reported second-quarter revenue of $59.9 million, an 11% year-over-year increase, with gross margins expanding to 53% and adjusted EBITDA of $18.1 million [8] - Cash reserves stood at $44.2 million, and cultivation volume reached 231,000 pounds during the quarter, with costs averaging $91 per pound [8] Cresco Labs (OTC: CRLBF) - Cresco Labs operates 71 Sunnyside dispensaries and focuses on both retail and wholesale, with significant brand development across various product categories [9][10] - The company posted revenue of $164 million in the second quarter of 2025, with an adjusted gross margin of 50.6% and adjusted EBITDA of approximately $41 million [11] - Cresco reported a net loss of $14 million, primarily from non-cash impairments, but has effectively controlled expenses, with selling, general, and administrative expenses at 31% of revenue [11] Investment Considerations - Investors are encouraged to apply technical analysis, monitoring support, resistance, and moving averages to improve timing in this volatile sector [12] - The upcoming catalysts, such as federal rescheduling and new state launches, make these three stocks—Green Thumb, Glass House, and Cresco—worth watching closely [12]

Industry Overview - The U.S. cannabis industry is projected to exceed $33 billion in sales for 2024, with potential annual revenues surpassing $50 billion by 2030, driven by new state markets and expanding consumer demand [1] - Recent discussions among U.S. lawmakers regarding cannabis reform and the recommendation from the Department of Health and Human Services to reclassify cannabis under the Controlled Substances Act have generated optimism for investors [1] Ancillary Cannabis Stocks - Ancillary stocks, which provide real estate, equipment, and financing, are essential in the cannabis market as they avoid plant-touching risks, offering safer exposure to industry growth [1] - Three key ancillary cannabis stocks to watch are Innovative Industrial Properties, Inc. (IIPR), NewLake Capital Partners, Inc. (NLCP), and Chicago Atlantic Real Estate Finance, Inc. (REFI) [3][5] Innovative Industrial Properties, Inc. (IIPR) - IIPR is the largest publicly traded cannabis REIT, owning over 100 properties across 19 states, primarily focused on leasing to state-licensed cannabis operators [7] - The company reported total revenue of $77.8 million, a 9% year-over-year increase, with net income of $40.5 million, highlighting its profitability [8] - IIPR maintains a high occupancy rate above 97% and pays a quarterly dividend of $1.80 per share, appealing to income-focused investors [9] NewLake Capital Partners, Inc. (NLCP) - NLCP owns approximately 33 properties, including 15 cultivation facilities and 18 dispensaries, operating under long-term triple-net leases across various states [12] - The company generated revenue of $51.2 million and net income of $26.1 million over the trailing twelve months, with a net margin of about 51% [14] - NLCP offers a quarterly dividend of $0.43 per share, translating to an annual yield of around 12%, making it attractive for income-oriented investors [15] Chicago Atlantic Real Estate Finance, Inc. (REFI) - REFI specializes in providing credit to licensed cannabis operators, having deployed over $2.8 billion in credit and equity investments across the sector [19] - The company reported $62 million in interest and dividend income, with total revenue of $56.6 million and net income of $38.1 million, resulting in a net margin near 67% [20][21] - REFI offers an annual dividend of $2.06 per share, yielding nearly 15%, and analysts project a price target near $20, indicating significant upside potential [21][22] Investment Outlook - As the cannabis industry matures, ancillary companies like IIPR, NLCP, and REFI provide reduced regulatory risks while capturing sector growth [23] - These companies present compelling opportunities for investors seeking exposure to cannabis without the volatility associated with plant-touching operators [23]

With Federal Legalization Stalled, Cannabis Companies Are Finding A New Green Rush In Europe https://t.co/b1tqd28dhe https://t.co/7Fqpdq8ca8 ...

Market Trends - Cannabis companies are exploring opportunities in the European market due to stalled federal legalization in the US [1] - A new "Green Rush" is emerging in Europe for cannabis businesses [1]

Financial Data and Key Metrics Changes - In Q3 fiscal 2025, gross sales increased by 73% year over year and 7.2% sequentially, reaching a record $110.2 million [28] - Net revenue also reached a record high, growing 72% year over year and 7.9% sequentially to $70.8 million [28] - Adjusted EBITDA for the quarter was $5.7 million, a 64% increase year over year [34] - Net loss for the quarter was $6.3 million compared to net income of $2.8 million in the prior year period [35] - Cash flow from operations was $14.6 million, a significant improvement from cash used of $3.7 million in the prior year [35] Business Line Data and Key Metrics Changes - Organigram maintained its position as the number one licensed producer in Canada with an 11.6% market share, leading in pre-rolls and vapes [7] - In the vape segment, Organigram held a 20.4% market share, while in the pre-roll segment, it held 8.3% [7] - The company achieved its highest edibles market share of 18.2% in the last twelve months [11] - International revenue reached $7.4 million, a 208% year over year increase [22] Market Data and Key Metrics Changes - The Canadian recreational cannabis market grew by 6.6% year over year, reaching $1.4 billion in retail sales [7] - Organigram's market share in flower increased to 10.6%, up 60 basis points from Q2 [7] - The beverage market share held by Organigram was 6.2% as of June [12] Company Strategy and Development Direction - The company is focused on balancing domestic and international market demands while expanding its product offerings [27] - Organigram is enhancing its operational capacity and efficiency, with significant investments in its facilities [16][20] - The company is optimistic about the long-term potential of the cannabis beverage market, especially with favorable regulatory changes in Canada [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a gross margin of approximately 35% for the full year, driven by seasonal throughput and synergies from the Motif acquisition [41][43] - The company remains cautious about shifting too much supply to international markets at the expense of domestic brands [29] - Management highlighted ongoing improvements in operational efficiency and the potential for margin expansion in the coming quarters [34][31] Other Important Information - The company is awaiting EU GMP certification, which is expected to enhance international sales and margins [26][56] - Management noted that approximately 27% of Moncton's harvest was seed-based, contributing to lower production costs [26] Q&A Session Summary Question: Outlook on gross margins and expected expansion - Management confirmed the expectation of a 35% average gross margin for the year, driven by seasonal throughput and synergies from the Motif acquisition [41][43] Question: Cultivation capacity and balancing domestic vs international demand - Management discussed ongoing capacity expansion projects and the reevaluation of previous investment plans to optimize production for both domestic and international markets [45][48] Question: Timing and impact of EU GMP certification - Management indicated that while the timing of the certification is uncertain, it will significantly enhance margins and reduce delays in product delivery [56][58] Question: Investment opportunities in the U.S. and potential federal reform - Management expressed excitement about the U.S. market but emphasized that current focus remains on international markets due to existing legal frameworks [66][67]

Regulatory Landscape & Policy Changes - The cannabis industry has been actively lobbying Washington, potentially leading to more favorable policies [2] - The Trump administration expressed support for cannabis and reducing uncertainty in the sector [2] - Rescheduling cannabis from Schedule I to Schedule III would significantly alter the industry's tax structure [2][4] - The FDA has acknowledged the medicinal use of cannabis in a 28-page memo [3] Market Dynamics & Investment Opportunities - State-by-state, cannabis legalization is consistently progressing, with adult, medical, and recreational markets being approved [6] - The cannabis market is estimated to be an $80 billion market, including adult, medical, and illicit sales [8] - Top-line growth is evident, attracting consumers seeking exposure to this growth [8] - Investing in the cannabis sector now allows investors to be ahead of institutional capital [8] Challenges & Considerations - Confusion exists regarding the business outlook due to complex legal and regulatory frameworks at both state and federal levels [5] - Restrictions on sales types vary across states where cannabis products are available [5] - Hemp-derived THC legalization through the farm bill adds complexity for investors [7] - Investing in the sector can be complicated, requiring a deep understanding of the industry [8]